. 2013 Jul 23;1(5):887–893. doi: 10.3892/mco.2013.153

Table III.

Relationships between mRNA levels and clinical characteristics.

Characteristic	Statistics	BRCA1	TYMS	STMN1	TOP2A	PDGFR	VEGFR2	KIT	HER2
Gender	χ²	3.042	7.846	0.255	5.702	1.318	0.255	1.771	0.008
	P-value	0.081	0.005	0.614	0.017	0.251	0.614	0.183	0.927
Age (years)	χ²	0.124	0.006	0.006	0.006	3.176	0.006	3.200	0.608
	P-value	0.725	0.939	0.939	0.939	0.075	0.939	0.074	0.436
Stage	χ²	1.455	1.769	4.989	3.949	0.626	9.081	10.277	8.388
	P-value	0.693	0.622	0.173	0.267	0.890	0.028	0.016	0.039
Primary tumor	χ²	4.832	1.482	4.314	3.665	3.829	6.149	10.267	1.799
	P-value	0.185	0.686	0.230	0.300	0.281	0.105	0.016	0.615
Lymph nodes	χ²	3.692	7.394	0.839	5.162	3.622	0.353	1.385	1.073
	P-value	0.297	0.060	0.840	0.160	0.305	0.950	0.709	0.784
Distant metastasis	χ²	0.036	0.095	0.036	0.653	0.328	7.222	1.709	4.183
	P-value	0.849	0.758	0.849	0.419	0.567	0.007	0.191	0.041
Histological type	χ²	16.481	8.074	1.831	5.713	1.075	1.075	3.255	6.618
	P-value	0.000	0.004	0.176	0.017	0.300	0.300	0.071	0.010
Differentiation	χ²	1.462	5.942	5.544	0.795	0.443	0.443	4.043	5.427
	P-value	0.481	0.051	0.063	0.672	0.801	0.801	0.132	0.066
Smoking history	χ²	6.867	5.888	0.268	8.106	4.988	0.507	1.357	0.085
	P-value	0.009	0.015	0.605	0.004	0.026	0.476	0.244	0.771

Statistics were calculated by the χ² test and the undetermined samples were not included. The cut-off point of the primary tumor was 3 cm. BRCA1, breast cancer 1; TYMS, thymidylate synthetase; STMN1, stathmin 1; TOP2A, topoisomerase II α; VEGFR2, vascular endothelial growth factor receptor 2; PDGFR, platelet-derived growth factor receptor; HER2, human epidermal growth factor receptor 2.